The near-patient molecular solutions market is estimated to register a magnificent CAGR of 8% during the forecast period. According to FMI, the market is projected to be valued at US$ 7.56 Billion by 2033, up from US$ 3.5 Billion
Smart apps, wearable gear, and biosensors are some of the emerging technologies in the healthcare business that are simple to connect to patients' general health. These advanced technologies are increasing the demand for near-patient molecular solutions during the forecast period.
| Attributes | Details |
|---|---|
| Near-patient Molecular Solutions Market (2023) | US$ 3.5 Billion |
| Near-patient Molecular Solutions Market (2033) | US$ 7.56 Billion |
| Near-patient Molecular Solutions Market CAGR (2023 to 2033) | 8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
The growing end-use sectors such as hospitals, home care, diagnostic laboratories, and research laboratories increase the market expansion during the forecast period. However, the market for near-patient molecular solutions increased from US$ 3.03 Billion between 2018 and 2022 with an impressive CAGR of 7.5%.
The rising improvement in healthcare devices and Smart applications with AI technology increases the adoption of near-patient molecular solutions. The key companies are paying attention to advancing the values of the near-patient molecular solutions market to provide effective treatment.
The global near-patient molecular solutions market is anticipated to be valued at US$ 7.56 Billion by 2032 with a CAGR of 8%.
By technology, the market is segmented into PCR (Polymerase Chain Reaction) based, Genetic sequencing-based, hybridization-based and microarray-based. The PCR-based segment dominates the global market by contributing a significant role during the forecast period.
The rising adoption of polymerase chain reaction technology to treat a patient is anticipated to boost the market expansion during the forecast period. The increase in the innovation of molecular diagnostic devices is likely to rise the demand for polymerase chain reaction technology.
By product type, the market is classified into cardiometabolic monitoring kits, infectious diseases testing kits, coagulation monitoring kits, pregnancy and fertility, and hematology testing kits. Infectious disease testing kits dominate the global market by capturing a relevant share during the forecast period. The growing prevalence of diseases such as SARS COV-19 is likely to increase the demand for infectious disease testing kits during the forecast period.
By end-use segment, the hospital's category dominates the market by occupying the highest share during the forecast period. Due to the rising number of patients treating their infectious diseases such as chronic, diabetes, and other diagnostic treatment during the forecast period. In addition, homecare, research laboratories, and diagnostic laboratories are other remaining categories that contribute a significant role in the market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
North America dominates the global market by securing a significant share during the forecast period. The USA is leading the global market with a rising number of clinical studies and good reimbursement policies for diagnostic procedures during the forecast period. In addition the growing demand for near-patient testing devices and the presence of prominent players increasing the market expansion during the forecast period.
The growing government support and investment among key companies are accelerating the demand for near-patient molecular solutions during the forecast period. However, the USA anticipated uplifting the market size with its new technologies and advanced healthcare infrastructure in the coming years.
The United Kingdom is anticipated to secure a significant share of the global market during the forecast period. The United Kingdom market has recently benefited from the increased availability of cutting-edge central laboratories for testing and well-known manufacturers.
The growing advanced automatic molecular testing device and research operation in the United Kingdom are increasing the market opportunities during the forecast period. In addition, rising well-equipped hospitals and a rising generic population are expected to drive the market share in recent years.
The Asia Pacific Region is advancing global marketing by capturing a significant share during the forecast period. The Asia Pacific is the fastest-growing region that rapidly expanding its market size in recent years. The rising disposable income and rapid urbanization are accelerating the demand for near-patient molecular solutions during the forecast period.
| Asian-countries | Korea |
|---|---|
| Driving Factors | The Korean nation is contributing a prominent role in the upsurge of the market size due to an increase the infectious diseases, a large patient population, and advanced healthcare equipment. The growing key healthcare manufacturers and development in the healthcare sector are surging the Korean near-patient molecular solutions market opportunities during the forecast period. |
| Asian-countries | Japan |
|---|---|
| Driving Factors | Japan is another nation in the region that contribute a prominent role in the global market during the forecast period. Rising rapid flue testing devices and innovations in the healthcare industry are accelerating the demand for near-patient molecular solutions during the forecast period. |
How are Start-up Companies Experimenting in the Near-patients Molecular Solutions Market?
| Company Name | Sherlock Biosciences |
|---|---|
| Founded Year | 2019 |
| Description | Sherlock Biosciences is a near-patient molecular solution USA-based start-up company founded in 2019. The start-up provides synthetic biology and improves the patient's health from the diagnostic. The company aims to provide better diagnostics treatment to the patient with faster, more effective, and affordable tests. They are advancing molecular testing devices to offer better diagnostic solutions. |
| Company Name | Nucleai |
|---|---|
| Founded Year | 2017 |
| Description | Nucleai is an Israel-based start-up company that provides AI-powered healthcare applications to clinicians and pharmaceutical companies. The start-up enhances the support of treatment and drug development with biomarker discovery technology. They are developing a better understanding of cancer biology, improving patient healthcare, and optimizing with real-world pathology and molecular datasets. The company is a campaign across the nation to raise awareness among patients and improve patients' health with the best diagnostic tools. |
| Company Name | Yemaachi Biotechnology |
|---|---|
| Founded Year | 2020 |
| Description | Yemaachi Biotechnology is an Africa-based Cancer research start-up company that redefined cancer-diagnosed treatment with their innovative and suitable biomedical research. The start-up provides advanced medical treatment across the nation with its research and development activities. The company partnered with the biotechnology and pharmaceutical industries to develop advanced therapeutics and molecular diagnostics with novel technology. The company also provides clinical services such as molecular cancer test services with prognostic testing and NGS-based screening. |
The market is consolidated by the number of prominent vendors in the region during the forecast period. Prominent vendors play a crucial role in the healthcare field to uplift the market size during the forecast period. These players are focusing on fulfilling the consumer's requirements as per their demand in recent years.
The prominent vendors are making several marketing strategies to acquire a lion’s share of the market. Innovating the relevant products through their research and development activities increases the market opportunities during the forecast period. Some of the marketing tactics adopted by these players include collaborations, partnerships, mergers, acquisitions, agreements, and product launches.
Recent Developments in the Driving Training Simulator Market
The near-patient molecular solutions market is valued at US$ 3.5 Million.
The near-patients molecular solutions market is likely to register a CAGR of 8% during the forecast period.
North America holds the most opportunities in the near-patient molecular solutions market.
1. Executive Summary | Near-Patient Molecular Solutions Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Technology
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2022 to 2032
5.3.1. PCR-based
5.3.2. Genetic Sequencing Based
5.3.3. Hybridization-based
5.3.4. Microarray-based
5.4. Y-o-Y Growth Trend Analysis By Technology, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Technology, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2022 to 2032
6.3.1. Infectious Diseases Testing Kits
6.3.2. Cardio-Metabolic Monitoring Kits
6.3.3. Pregnancy and Fertility
6.3.4. Coagulation Monitoring Kits
6.3.5. Hematology Testing Kits
6.3.6. Urinalysis Testing Kits
6.3.7. Glucose Monitoring Kits
6.3.8. Drugs-of-abuse Testing Kits
6.3.9. Testing Kits
6.3.10. Fecal Occult Testing Kits
6.3.11. Tumor/Cancer Markers
6.3.12. Cholesterol Test Strips
6.3.13. Other Products
6.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Product Type, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032
7.3.1. Hospitals
7.3.2. Homecare
7.3.3. Diagnostic Laboratories
7.3.4. Research Laboratories
7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa(MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Technology
9.2.3. By Product Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Technology
9.3.3. By Product Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Technology
10.2.3. By Product Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Technology
10.3.3. By Product Type
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Technology
11.2.3. By Product Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Technology
11.3.3. By Product Type
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Technology
12.2.3. By Product Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Technology
12.3.3. By Product Type
12.3.4. By End User
12.4. Key Takeaways
13. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of Middle East and Africa(MEA)
13.2.2. By Technology
13.2.3. By Product Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Technology
13.3.3. By Product Type
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Technology
14.1.2.2. By Product Type
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Technology
14.2.2.2. By Product Type
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Technology
14.3.2.2. By Product Type
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Technology
14.4.2.2. By Product Type
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Technology
14.5.2.2. By Product Type
14.5.2.3. By End User
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Technology
14.6.2.2. By Product Type
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Technology
14.7.2.2. By Product Type
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Technology
14.8.2.2. By Product Type
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Technology
14.9.2.2. By Product Type
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Technology
14.10.2.2. By Product Type
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Technology
14.11.2.2. By Product Type
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Technology
14.12.2.2. By Product Type
14.12.2.3. By End User
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Technology
14.13.2.2. By Product Type
14.13.2.3. By End User
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Technology
14.14.2.2. By Product Type
14.14.2.3. By End User
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Technology
14.15.2.2. By Product Type
14.15.2.3. By End User
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Technology
14.16.2.2. By Product Type
14.16.2.3. By End User
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Technology
14.17.2.2. By Product Type
14.17.2.3. By End User
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Technology
14.18.2.2. By Product Type
14.18.2.3. By End User
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Technology
14.19.2.2. By Product Type
14.19.2.3. By End User
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2021
14.20.2.1. By Technology
14.20.2.2. By Product Type
14.20.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Technology
15.3.3. By Product Type
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Abbott Laboratories, Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Roche Diagnostics Limited
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Siemens AG
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Beckman Coulter, Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Becton, Dickinson, and Company
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Johnson & Johnson
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. PTS Diagnostics
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Nova Biomedical
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Bayer Healthcare
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. BioMerieux
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Near-Patient Molecular Solutions Market
